DVAX - NASDAQ

Dynavax Technologies Corporation

DVAX·NASDAQ

$15.50

+0.0000%

HealthcareDrug Manufacturers - Specialty & Generic

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.82B

EPS0.2100

P/E Ratio60.81

Earnings Date05/04/2026

986.26M

Assets

-1%

3Y-5.0%

5Y+253.0%

10Y+355.0%

389.46M

Total Liabilities

3Y-52.0%

5Y+44.0%

10Y+1218.0%

596.80M

Total Equity

-4%

3Y+168.0%

5Y+7099.0%

10Y+219.0%

Dynavax Technologies Corporation Funding & Solvency Profile

DVAX · NASDAQ

Current Assets

Cash & Cash Equivalents95.88M

Net Receivables46.91M

Inventory70.05M

Other Current Assets18.15M

Total Current Assets849 M

Non-Current Assets

Property, Plant & Equipment60.61M

Goodwill & Intangible Assets1.95M

Long-Term Investments71.58M

Other Non-Current Assets3.18M

Total Non-Current Assets135 M

Total Assets

986.26M

Financial Health Analysis

Current Ratio

10.80x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.65x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

770 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

86% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Dynavax Technologies Corporation Balance Sheet

DVAX • NASDAQ

Dynavax Technologies Corporation Balance Sheet	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006	Dec 2005
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	95.9M	150.3M	202M	436.2M	32.1M	39.9M	49.3M	26.6M	24.3M	44.8M	49.5M	23.1M	7.6M	31.9M	22.5M	36.7M	28.1M	14.3M	14.2M	8.7M
Short-Term Investments	618M	592M	422.4M	109.8M	133M	111.2M	96.2M	165.3M	57.1M	151.3M	73.1M	166.3M	117.5M	82M	49.7M	0.0	40.4M	42.3M	58.7M	66.4M
Cash & Short-Term Investments	713.8M	742.3M	624.4M	546M	165M	151.1M	145.5M	191.9M	81.4M	196.1M	122.7M	189.4M	125.1M	114M	72.2M	36.7M	68.5M	56.6M	72.8M	75.1M
Net Receivables	46.9M	44.5M	147.5M	131.8M	22.7M	8.9M	3.7M	854K	1.3M	1.4M	727K	1.6M	1M	9.5M	1M	895K	6.4M	7.2M	2.2M	689K
Accounts Receivables	45.3M	40.6M	145.1M	116.2M	22.3M	8.9M	3.7M	854K	1.3M	1.4M	727K	1.6M	1M	9.5M	1M	895K	6.4M	7.2M	2.2M	689K
Other Receivables	1.6M	3.9M	2.4M	15.6M	356K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	70.1M	53.3M	59.4M	61.3M	63.7M	41.3M	19M	312K	-8.2M	-3.8M	-4.8M	0.0	-3.1M	0.0	0.0	0.0	0.0	6.5M	257K	0.0
Prepaids	0.0	0.0	0.0	159.7M	38.6M	7.4M	6.1M	3.7M	6.8M	2.4M	4.1M	1.4M	2.1M	1.1M	1.4M	586K	991K	6M	673K	1.3M
Other Current Assets	18.1M	19M	85.6M	73.8M	0.0	0.0	6.1M	1.3M	6.8M	0.0	0.0	0.0	0.0	0.0	1.4M	586K	668K	408K	13.8M	408K
Total Current Assets	848.9M	859.1M	917M	972.5M	290M	208.7M	164.6M	191.9M	81.4M	196.1M	122.7M	192.4M	125.1M	124.6M	74.5M	38.9M	76.5M	101.9M	89.7M	77.5M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	60.6M	61.6M	63.3M	61M	57.2M	62.3M	17.1M	16.6M	17.2M	13.8M	7.9M	8.7M	8M	6.2M	6.4M	8M	9.5M	7.3M	5.2M	2.2M
Goodwill	1.9M	2.1M	2M	2.1M	2.3M	2.1M	2.1M	2.2M	2M	2M	2.3M	2.6M	2.5M	2.3M	2.3M	2.3M	2.3M	2.3M	2.3M	0.0
Intangible Assets	0.0	0.0	0.0	0.0	0.0	2.5M	11.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	299K	1.3M	2.3M	3.2M	4.4M	0.0
Goodwill & Intangible Assets	1.9M	2.1M	2M	2.1M	2.3M	4.6M	13.9M	2.2M	2M	2M	2.3M	2.6M	2.5M	2.3M	2.6M	3.6M	4.6M	5.6M	6.7M	0.0
Long-Term Investments	71.6M	0.0	0.0	0.0	0.0	0.0	619K	629K	602K	0.0	0.0	0.0	0.0	-3K	0.0	0.0	0.0	0.0	0.0	0.0
Tax Assets	0.0	0.0	0.0	0.0	0.0	0.0	-619K	-629K	-602K	0.0	0.0	0.0	0.0	3K	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	3.2M	74.3M	3.5M	3.6M	3.8M	3.6M	15.4M	8.1M	9.1M	4.7M	5.4M	959K	4.2M	1M	719K	0.0	0.0	5.6M	1.3M	412K
Total Non-Current Assets	137.3M	138M	68.9M	66.7M	63.3M	70.4M	46.3M	26.9M	28.3M	20.5M	15.6M	12.2M	14.6M	9.5M	9.7M	11.6M	14.1M	18.5M	13.2M	2.6M
Total Assets	986.3M	997.1M	985.9M	1B	353.3M	279.1M	210.9M	218.8M	109.7M	216.6M	138.3M	204.6M	139.8M	134.1M	84.2M	50.5M	90.6M	120.4M	102.9M	80.1M
LIABILITIES
CURRENT LIABILITIES
Total Payables	9.1M	5.2M	3.2M	2.6M	3.3M	9.3M	5.3M	4.5M	3.8M	3.4M	1.2M	1.9M	2.2M	2M	2.3M	1.7M	905K	4.4M	2.2M	952K
Accounts Payable	9.1M	5.2M	3.2M	2.6M	3.3M	9.3M	5.3M	4.5M	3.8M	3.4M	1.2M	1.9M	2.2M	2M	2.3M	1.7M	905K	4.4M	2.2M	952K
Accrued Expenses	65.4M	52.4M	143.2M	183.3M	21.9M	18.9M	8.1M	14.1M	16.2M	22.7M	13.3M	8.2M	10.1M	8.2M	10.9M	7.5M	6.8M	12.1M	10.7M	3.8M
Short Term Debt	4.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.8M	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	4.5M	3.6M	2.6M	3.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	349.9M	38.2M	0.0	0.0	0.0	0.0	2.7M	5.9M	6.1M	6.8M	4.2M	1.4M	2.7M	33.1M	3.4M	778K	750K
Other Current Liabilities	22K	24K	0.0	18M	10.7M	24.8M	24.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6M	0.0	0.0	0.0	0.0
Total Current Liabilities	78.6M	62.2M	150.1M	556.4M	77.4M	53M	38M	18.6M	20M	28.8M	20.3M	16.2M	19M	27.2M	14.7M	14.5M	40.9M	19.9M	13.7M	5.5M
NON-CURRENT LIABILITIES
Long Term Debt	223.9M	222.7M	221.6M	220.5M	179.8M	178.6M	100.9M	0.0	0.0	0.0	9.6M	0.0	0.0	0.0	11.8M	9.3M	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7M	12.8M	1.2M	12.1M	6.4M	5.7M	17.1M	18.5M	40.8M	10M	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-11.8M	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	60.6M	60.4M	384K	5.7M	2.6M	1.3M	8.9M	643K	20.5M	26.9M	15.5M	963K	12.9M	617K	0.0	3.2M	15.1M	20.6M	117K	187K
Total Non-Current Liabilities	310.8M	312.8M	254.8M	260.5M	217.2M	217.7M	109.8M	19.2M	20.5M	29.6M	37.8M	2.1M	24.9M	7M	17.4M	29.6M	33.6M	61.4M	10.1M	187K
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-18.6M	-20M	-28.8M	-20.3M	0.0	-19M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations	26.4M	34.2M	36.4M	36.9M	38M	37.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	389.5M	375M	404.8M	816.9M	294.6M	270.8M	147.8M	19.2M	20.5M	29.6M	37.8M	18.3M	24.9M	34.2M	32.1M	44.1M	74.5M	81.3M	23.8M	5.7M
SHAREHOLDERS' EQUITY
Common Stock	125K	130K	128K	123K	110K	84K	63K	62K	39K	38K	26K	263K	183K	155K	116K	54K	40K	40K	40K	30K
Additional Paid-In Capital	1.5B	1.6B	1.5B	1.4B	1.4B	1.2B	1.1B	1.1B	905M	889.7M	695.1M	688.4M	550.7M	466.3M	369.7M	266.1M	262.6M	258.3M	244.8M	192.8M
Retained Earnings	-903.3M	-930.6M	-924.2M	-1.2B	-1.3B	-1.2B	-1.1B	-907.3M	-812.2M	-699.7M	-592.9M	-502.2M	-435.5M	-365.5M	-316.9M	-259.6M	-248.7M	-227.9M	-167.9M	-115.9M
Accumulated Other Comprehensive Income/Loss	-4.7M	-2.1M	-5.4M	-2.3M	273K	-2.4M	-2M	-881K	-3.6M	-2.9M	-1.7M	-148K	-595K	-1M	-746K	-168K	-354K	398K	172K	-2.6M
Total Stockholders' Equity	596.8M	622.1M	581M	222.4M	58.7M	8.3M	63.1M	199.5M	89.2M	187.1M	100.5M	186.3M	114.8M	99.9M	52.1M	6.4M	13.5M	30.8M	77.1M	74.4M
Total Equity	596.8M	622.1M	581M	222.4M	58.7M	8.3M	63.1M	199.5M	89.2M	187.1M	100.5M	186.3M	114.8M	99.9M	52.1M	6.4M	16.2M	39.1M	79.1M	74.4M
Minority Interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6M	8.3M	2M	0.0
SUMMARY
Total Liabilities & Equity	986.3M	997.1M	985.9M	1B	353.3M	279.1M	210.9M	218.8M	109.7M	216.6M	138.3M	204.6M	139.8M	134.1M	84.2M	50.5M	90.6M	120.4M	102.9M	80.1M
Total Investments	689.5M	592M	422.4M	109.8M	133M	111.2M	96.2M	165.3M	57.1M	151.3M	73.1M	166.3M	117.5M	82M	49.7M	0.0	40.4M	42.3M	58.7M	66.4M
Total Debt	254.4M	256.9M	258M	257.4M	217.8M	216.4M	100.9M	0.0	0.0	0.0	9.6M	0.0	0.0	12.8M	11.8M	9.3M	0.0	0.0	0.0	0.0
Net Debt	158.5M	106.6M	56M	-178.8M	185.8M	176.6M	51.5M	-26.6M	-24.3M	-44.8M	-40M	-23.1M	-7.6M	-19.1M	-10.7M	-27.4M	-28.1M	-14.3M	-14.2M	-8.7M
Shares Outstanding	117,421,601	117,421,601	117,421,601	117,421,601	117,421,601	117,421,601	117,421,601	117,421,601	117,421,601	117,421,601	117,421,601	117,421,601	117,421,601	117,421,601	117,421,601	117,421,601	117,421,601	117,421,601	117,421,601	117,421,601

SEC Filings

DVAX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	February 10, 2026	February 10, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 29, 2025	December 23, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 05, 2025	November 05, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 05, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 16, 2025	October 15, 2025	2025	View Filing
8-K 8-K 2025 N/A	August 21, 2025	August 21, 2025	2025	View Filing
8-K 8-K 2025 N/A	August 07, 2025	August 07, 2025	2025	View Filing
10-Q 10-Q 2025 Q2 Q2	August 07, 2025	June 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	June 17, 2025	June 11, 2025	2025	View Filing
8-K 8-K 2025 N/A	May 13, 2025	May 08, 2025	2025	View Filing

Showing 1 to 10 of 522 filings

Related Guides

Blog Categories

Continue your DVAX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.